Akebia Therapeutics, Inc.
Akebia Therapeutics develops and commercializes therapeutics for kidney diseases. Lead product Vafseo (vadadustat) treats anemia due to chronic kidney disease in dialysis-dependent and non-dialysis patients. Offers Auryxia for serum phosphorus level control and iron deficiency anemia treatment. Product pipeline includes AKB-9090 for critical-care indications and AKB-10108 for premature birth-related conditions. Has collaborations with Mitsubishi Tanabe Pharma and Janssen Pharmaceutica NV. Incorporated in 2007, headquartered in Cambridge, Massachusetts.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |